Novo Nordisk’s stock is rallying as Hims & Hers’ stock falters. An Ozempic alternative won’t be available for long.
Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much longer.
Novo Nordisk's Ozempic And Wegovy No Longer on FDA Shortage List, Faces Lawsuit Over Decision
A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms ...
Medpage Today on MSN14d
Ozempic, Wegovy Shortage Is Officially Over
The shortage of semaglutide injections (Ozempic, Wegovy) is over, the FDA announced on Friday. The agency, along with maker ...
Morningstar10d
Novo Nordisk's stock is rallying as Hims & Hers' stock falters. An Ozempic alternative won't be available for long.
Hims & Hers Health Inc.'s stock plunged last week when the Food and Drug Administration said ... the chemical name of another Novo Nordisk product, Saxenda. Analysts at Citi said Hims & Hers ...